LPCN - Lipocine Inc.

Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs.

Sector
Healthcare
Industry
Biotechnology
Market Cap
$13.2M
Beta
0.50
52-Week Range
1.81-12.37
CEO
Mahesh V. Patel
Employees
16
IPO Date
Oct 22, 2013
Exchange
NASDAQ

LPCN Options Snapshot

Options pricing data for LPCN is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.

What This Page Covers

The LPCN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.

Frequently asked LPCN overview questions

What is LPCN?
LPCN is the ticker symbol for Lipocine Inc., a listed security. Lipocine Inc. , a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. Listed on NASDAQ. LPCN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
What are LPCN's key statistics?
Lipocine Inc. (LPCN) carries a market capitalization of $13.2M, beta of 0.50 relative to the broader market, 52-week range of 1.81-12.37. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
What sector or industry does LPCN belong to?
Lipocine Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LPCN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
How current is the LPCN data on this page?
Options snapshots refresh after each trading session; if no snapshot is currently posted for LPCN, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).